DaShenLin Pharmaceutical Group Co., Ltd.

SHSE:603233 Stock Report

Market Cap: CN¥18.6b

DaShenLin Pharmaceutical Group Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Guoqiang Ke

Chief executive officer

CN¥2.3m

Total compensation

CEO salary percentagen/a
CEO tenure5.7yrs
CEO ownership0.02%
Management average tenureno data
Board average tenure1.7yrs

Recent management updates

Recent updates

Take Care Before Diving Into The Deep End On DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)

Sep 30
Take Care Before Diving Into The Deep End On DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)

DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Sep 03
DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

DaShenLin Pharmaceutical Group (SHSE:603233) May Have Issues Allocating Its Capital

Aug 20
DaShenLin Pharmaceutical Group (SHSE:603233) May Have Issues Allocating Its Capital

Not Many Are Piling Into DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Stock Yet As It Plummets 27%

Jun 17
Not Many Are Piling Into DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Stock Yet As It Plummets 27%

Does DaShenLin Pharmaceutical Group (SHSE:603233) Have A Healthy Balance Sheet?

Jun 09
Does DaShenLin Pharmaceutical Group (SHSE:603233) Have A Healthy Balance Sheet?

Are Investors Undervaluing DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) By 30%?

May 21
Are Investors Undervaluing DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) By 30%?

Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) Earnings

May 06
Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) Earnings

Investors Could Be Concerned With DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On Capital

Apr 09
Investors Could Be Concerned With DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On Capital

Lacklustre Performance Is Driving DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Low P/E

Mar 17
Lacklustre Performance Is Driving DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Low P/E

CEO

Guoqiang Ke (42 yo)

5.7yrs

Tenure

CN¥2,308,800

Compensation

Mr. Guoqiang Ke is General Manager of DaShenLin Pharmaceutical Group Co., Ltd. from February 28, 2019 and serves as DIrector since February 03, 2023. He was Deputy General Manager of DaShenLin Pharmaceutic...


Board Members

NamePositionTenureCompensationOwnership
Guoqiang Ke
GM & Director1.7yrsCN¥2.31m0.025%
CN¥ 4.6m
Qun Fei Tan
Deputy GM & Director1.7yrsCN¥2.05m0.024%
CN¥ 4.4m
Zhi Hui Chen
Chairman of Supervisory Board & Deputy Director of Human Resources Department - Guangdong Provinceno datano data0.012%
CN¥ 2.2m
Yun Feng Ke
Chairman of the Boardno dataCN¥2.49m21.3%
CN¥ 4.0b
Guo Liu
Independent Directorno dataCN¥73.40kno data
Zu Yao Su
Independent Directorno dataCN¥80.00kno data
Jie Li
Directorno datano datano data
Li Ping Lu
Independent Directorno dataCN¥80.00kno data
Jinshu Shi
Staff Supervisorno datano data0.00055%
CN¥ 102.0k
Wensheng Chen
Supervisor1.7yrsno datano data

1.7yrs

Average Tenure

54yo

Average Age

Experienced Board: 603233's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.